Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Over 1 billion people, including 500 million children, in the poorest regions of the world, are affected by neglected diseases that debilitate, disfigure or kill.

DNDi’s research and development approach is driven by the real day-to-day needs of patients and healthcare providers.

By connecting public and private partners, DNDi synergizes expertise and capitalizes upon the best science. 

DNDi also works to strengthen the health R&D field in the countries where the diseases occur in order to reinforce capacities for sustainable change.

Major progress has been made with six new treatments made available since the creation of DNDi, in 2003. However, major breakthroughs are still needed to treat neglected patients: Entirely new, affordable, and adapted drugs will change the lives of millions of people.

SPOTLIGHT
«
»

Sore to the Skin: Cutaneous Leishmaniasis

Cutaneous leishmaniasis may not be fatal, but it has a devastating impact on people’s lives. DNDi travelled to Colombia to document the impact of this disfiguring disease. More

Viewpoint: Bernard Pécoul

Bernard Pécoul writes about the convergence of innovation and access crises, challenging public leadership to respond. More

The Reality of Paediatric HIV

A mother, a doctor and a nurse speak about the reality of paediatric HIV in these short video clips. More

Partnership with Bayer to fight river blindness

Bayer HealthCare and DNDi have signed an agreement under which Bayer will provide the active ingredient emodepside to develop a new drug to treat river blindness. More

Pilot Pooled Fund for R&D

This recent paper commissioned by DNDi examines the possibilities of creating a pooled international R&D fund for the Demonstration Projects selected as part of the process following on the report of the WHO Consultative Expert Working Group on R&D (CEWG). More

DNDi NEWS

   

March 17-18, 2015GLOBVAC Conference 2015Oslo, NorwayDNDi participated in a symposium on sleeping sickness.

April 16-18, 2015British Society of Parasitology Spring Meeting 2015Liverpool, UKDNDi Discovery & Preclinical Director, Robert Don, will be presenting on R&D for neglected patients.

May 20-21, 2015ISNTD d3 2015London, United KingdomDNDi will be presenting on drug discovery for leishmaniasis and Chagas disease.

See all events

DNDi WORLDWIDE

REPORT: 10 YEARS OF DNDi

DNDi Model Paper
DNDi has issued a report that explores the lessons learned from a decade of R&D of new treatments for neglected diseases via a cost-effective, innovative, not-for-profit drug development model. Read more

TWITTER

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License